BrightEdge HAS INVESTED in **18 COMPANIES** with the POTENTIAL to IMPACT **1.5M+ PATIENTS*** and THEIR FAMILIES IN THE FIGHT AGAINST CANCER

**BY THE NUMBERS**

ACS Impact Venture Fund $78M GROSS ASSET VALUE

$28.9M $9.7M IN GAINS ON $28.9M IN INVESTMENTS

$3.1B RAISED by portfolio companies to advance PATIENT-CENTRIC INNOVATIONS such as therapeutics, diagnostics, devices and other technologies

4 NEW INVESTMENTS and 6 FOLLOW-ON INVESTMENTS ACROSS 5 PORTFOLIO COMPANIES

DEFINING IMPACT AND INNOVATION BY:

- **Partnering** with ACS** Discovery Research to narrow the gap between scientific grantmaking and equity investments.
- **Identifying** and **enabling** the next generation of **cancer-fighting entrepreneurs and leaders**.
- **Mobilizing** collaborator networks to **accelerate** and **deepen impact of investments**.

BrightEdge, LLC is the American Cancer Society’s innovation and impact investing arm. To learn more about BrightEdge and read the 2022 Annual Report, visit acsbrightedge.org.

*Cancer Impact Investment Framework™ is a proprietary and unique framework that assesses investment impact across American Cancer Society mission priority areas and cancer care continuum. **The American Cancer Society is the leading cancer-fighting organization with a vision of ending cancer as we know it, for everyone. To learn more about ACS, visit cancer.org